



GENELABS TECHNOLOGIES, INC.

NEWS RELEASE

CONTACT:

Irene Chow, Ph.D.
Genelabs Technologies, Inc.
415-369-9500

Andrea A. Boscoe
Genelabs Technologies, Inc.
415-369-9592 ext. 303

Mark Brand
Pondel Parson & Wilkinson
310-207-9300

FOR IMMEDIATE RELEASE

**GENELABS TECHNOLOGIES, INC. LICENSES PROMISING
LUPUS THERAPY**

**STANFORD UNIVERSITY SCIENTIST REPORTS PHASE II FINDINGS AT SCIENCE
CONFERENCE**

Redwood City, California – November 11, 1993 – Genelabs Technologies, Inc. (NASDAQ: GNLB) today announced the signing of an exclusive licensing agreement with Stanford University of Stanford, California for the development of dehydroepiandrosterone (DHEA), a drug for the treatment of Systemic Lupus Erythematosus (SLE, lupus).

Under the terms of agreement, Genelabs receives exclusive worldwide marketing and sublicensing rights to Stanford's DHEA patent and clinical results while Stanford receives milestone and royalty payments based on future clinical development goals and sales figures. Genelabs assumes management of the drug's future development and, upon regulatory approval, will market DHEA worldwide.

The agreement was announced in conjunction with a presentation by Ronald van Vollenhoven, M.D., Ph.D., senior fellow in the division rheumatology of Stanford University's School of Medicine of the results of a double-blind, randomized, placebo-controlled Phase II study testing DHEA in lupus patients. Dr. van Vollenhoven's results were presented at the 57th Annual meeting of the American College of Rheumatology in San Antonio, Texas. In addition to Dr. van Vollenhoven, principal investigators include James L. McGuire, M.D., associate professor of medicine and chief of staff of Stanford University Hospital and Edgar Engleman, M.D., professor of pathology and medicine for Stanford University.

- more -

The study involved 30 patients with mild to moderate lupus. Randomized patients received either DHEA or placebo daily over a three month study period. Patients were evaluated against four parameters: patient self-assessment, physician assessment, systemic lupus erythematosus disease activity index (SLEDAI) and dose of prednisone, a drug commonly used to treat lupus.

Whereas the placebo treated patients failed to improve during the study, the DHEA treated patients showed improvement in all four parameters. The results supported earlier, open-label studies by the Stanford group, which suggested that DHEA treatment is beneficial in lupus.

"We believe that these results indicate that DHEA is a potentially effective drug treatment against lupus," said Irene Chow, Ph.D., president of Genelabs' pharmaceutical division. Moreover, the licensing of DHEA significantly strengthens our product pipeline," Chow noted.

DHEA, a naturally occurring hormone produced by the adrenal glands, is known to be present in abnormally low levels in lupus patients. Previous studies have suggested that hormonal influences played a key role in the development and progression of the disease. The precise mechanism responsible for the therapeutic effect of DHEA remains to be determined.

"We have been particular impressed with the tolerability of DHEA in woman with lupus," said James L. McGuire, M.D., associate professor of medicine and chief of staff of Stanford University Hospital. "Although our experience is limited with DHEA, patients showed a consistent improvement in all parameters studied," Dr. McGuire added.

Lupus, which affects an estimated 135,000 Americans, is a chronic, autoimmune, inflammatory disease, that affects the skin, joints, kidneys, nervous system, and serous membranes lining the lungs, heart, and abdominal cavity. Lupus is 3-4 times more common in women than men.

Genelabs Technologies, Inc. is a human healthcare products company utilizing proprietary technologies to address the global need to diagnose, prevent and treat infectious diseases and cancer. Genelabs has 215 employees in facilities located in Redwood City, California; San Antonio, Texas; Geneva, Switzerland; Leuven, Belgium; Taiwan, ROC; and Singapore.